Epigenetic Factors of Colorectal Adenoma in Korean
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age19-85
SponsorBundang CHA Hospital
About this trial
This study aims to explore epigenetic factors associated with colorectal adenoma (CRA) in the Korean population. CRA is a key precancerous lesion in the adenoma-carcinoma sequence, and identifying methylated genetic markers may improve early detection and risk stratification for colorectal cancer (CRC).
A total of 32 patients undergoing colonoscopic polypectomy will be enrolled. Adenomatous and adjacent normal tissues will be collected for deoxyribonucleic acid (DNA) extraction and bisulfite conversion. Quantitative methylation-specific polymerase chain reaction (qMSP) and Sanger sequencing will be used to assess the methylation status of candidate genes (SFRP2, TFPI2, SEPT9, and SDC2). Stool samples will also be analyzed by whole-genome sequencing (WGS) to evaluate microbiome and genetic profiles.
The study seeks to determine whether methylation levels of these genes are significantly elevated in adenoma tissue compared with normal mucosa, thereby identifying potential biomarkers for colorectal neoplasia surveillance and personalized colonoscopy follow-up intervals.
Eligibility criteria
Qualifiers
Adults aged 19-85 years
Undergoing colonoscopic polypectomy for colorectal adenoma
Able to understand the study purpose and provide written informed consent
Adequate tissue available for both adenoma and adjacent normal mucosa sampling
Disqualifiers
History of colorectal cancer, inflammatory bowel disease, or hereditary colorectal cancer syndrome (e.g., FAP, Lynch syndrome)
Previous colorectal surgery that may alter anatomy or pathology
Inadequate sample quality or failure of DNA extraction
Refusal or withdrawal of informed consent
Trial design
Treatments tested in this trial
- Not listed
Trial groups
32 Participants
are grouped into 1 trial groupSponsors and collaborators
Source ClinicalTrials.gov